Compare Msci Inc (MSCI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Sana Biotechnology Inc — how do they compare? Msci Inc trades at $562 (market cap $40.84B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Msci Inc is far larger — about 36.1× Sana Biotechnology Inc's market cap, and Msci Inc pays a 1.46% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MSCI | SANA | |
|---|---|---|
Market Cap | $40.84B | $1.13B |
Sector | Financials | Health |
52-Week High | $643.83 | $5.92 |
52-Week Low | $511.84 | $2.68 |
Enterprise Value | $47.00B | $1.05B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.01, down slightly (-0.01%) with a bearish technical signal. The company maintains strong fundamentals with $3.13B revenue, 40.73% net margin, and consistent earnings beats in three of the last four quarters. Recent acquisitions and strategic partnerships enhance its private markets platform. Analyst consensus remains strongly bullish with a $728.14 price target, representing 29% upside potential from current levels.
The outlook remains positive given MSCI's recurring revenue model, high client retention, and secular growth in private markets. Key risks include execution of recent acquisitions and market sensitivity to index performance. With strong profitability and Wall Street support, the stock presents a compelling long-term opportunity despite near-term technical weakness.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
